|
Adverse events occurring in ≥ 3% of patients in any treatment group |
||
| Number (%) of patients with adverse event |
||
|
|
||
| Adverse event |
Rosuvastatin (n = 233) |
Atorvastatin (n = 236) |
|
|
||
| Nasopharyngitis |
23 (9.9) |
19 (8.1) |
| Myalgia |
13 (5.6) |
7 (3.0) |
| Inadequately controlled diabetes mellitus |
14 (6.0) |
11 (4.6) |
| Constipation |
9 (3.9) |
6 (2.5) |
| Headache |
6 (2.6) |
7 (3.0) |
| Urinary tract infection |
9 (3.9) |
2 (0.9) |
| Arthralgia |
1 (0.4) |
9 (3.8) |
Berne et al. Cardiovascular Diabetology 2005 4:7 doi:10.1186/1475-2840-4-7 |
||